ORIC® Pharmaceuticals Reports Third Quarter 2024 Financial Results and Operational Updates
Presented preclinical data further supporting the potential best-in-class profile of ORIC-114 to treat EGFR exon 20 insertions and other atypical ...
manilatimes12 小时
PLBY Group Reports Third Quarter 2024 Financial Results
LOS ANGELES, Nov. 12, 2024 (GLOBE NEWSWIRE) -- PLBY Group, Inc. (NASDAQ: PLBY) ("PLBY Group” or the "Company”), a leading ...